{"id":"NCT00972283","sponsor":"Novo Nordisk A/S","briefTitle":"Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes","officialTitle":"NN1250-3582: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing Efficacy and Safety of SIBA and Insulin Glargine Both Administered Once Daily in a Basal-bolus Regimen With Insulin Aspart as Mealtime Insulin ± Treatment With Metformin, ± Pioglitazone in Subjects With Type 2 Diabetes Currently Treated With Insulin Qualifying for Intensified Treatment/NN1250-3667: An Extension Trial to NN1250-3582 Comparing Safety and Efficacy of NN1250 and Insulin Glargine, Both With Insulin Aspart as Meal-time Insulin ± OADs in Type 2 Diabetes (BEGIN™: BB)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-09-01","primaryCompletion":"2010-10-28","completion":"2010-10-28","firstPosted":"2009-09-04","resultsPosted":"2015-11-13","lastUpdate":"2017-04-06"},"enrollment":1006,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"insulin degludec","otherNames":[]},{"type":"DRUG","name":"insulin glargine","otherNames":[]},{"type":"DRUG","name":"insulin aspart","otherNames":[]}],"arms":[{"label":"IDeg OD","type":"EXPERIMENTAL"},{"label":"IGlar OD","type":"ACTIVE_COMPARATOR"}],"summary":"This trial is conducted in Africa, Asia, Europe, and the United States of America (USA).\n\nThe aim of this clinical trial is to compare NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar) plus insulin aspart (IAsp) with/without metformin and with/without pioglitazone in subjects with type 2 diabetes (main period) followed by investigating the long-term safety in terms of comparing NN1250 with insulin glargine plus insulin aspart with or without metformin and with or without pioglitazone in subjects with type 2 diabetes.\n\nAll oral anti-diabetic drug (OAD) treatment will be discontinued, if applicable, when trial participant enters the trial (NN1250-3582) with the exception of metformin and pioglitazone.\n\nSubjects who consent to participate in the extension trial (NN1250-3667) will continue to receive the treatment to which they were randomly allocated in the 52 week trial NN1250-3582.\n\nThe main period is registered internally at Novo Nordisk as NN1250-3582 while the extension period is registered as NN1250-3667.","primaryOutcome":{"measure":"Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment","timeFrame":"Week 0, Week 52","effectByArm":[{"arm":"IDeg OD","deltaMin":-1.17,"sd":1.03},{"arm":"IGlar OD","deltaMin":-1.29,"sd":0.98}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":6},"locations":{"siteCount":136,"countries":["United States","Bulgaria","Germany","Hong Kong","Ireland","Italy","Romania","Russia","Slovakia","South Africa","Spain","Turkey (Türkiye)"]},"refs":{"pmids":["23130654","26484727","24170235","26121451","26232910","25081590","24812526","22521072","25387855","26582052","28210866"],"seeAlso":["http://novonordisk-trials.com"]},"adverseEventsSummary":{"seriousAny":{"events":139,"n":753},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Headache","Diarrhoea","Cough"]}}